Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives-Reference-Cited by-同舟云学术

Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives

Published:2024-03-15 Issue:4 Volume:17 Page:323-347
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Toledo Belén¹²,Deiana Chiara³,Scianò Fabio²⁴,Brandi Giovanni³⁵,Marchal Juan Antonio⁶⁷⁸⁹,Perán Macarena¹⁶⁹,Giovannetti Elisa²¹⁰¹¹

Affiliation:

1. Department of Health Sciences, University of Jaén, Jaén, Spain

2. Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center (VUmc), Amsterdam, The Netherlands

3. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

4. Lumobiotics GmbH, Karlsruhe, Germany

5. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

6. Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada, Spain

7. Instituto de Investigación Sanitaria ibs. GRANADA, Hospitales Universitarios de Granada-Universidad de Granada, Granada, Spain

8. Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada, Spain

9. Excellence Research Unit “Modeling Nature” (MNat), University of Granada, Granada, Spain

10. Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, Pisa, Italy

11. Cancer Pharmacology Lab, Associazione Italiana per la Ricerca sul Cancro (AIRC) Start-Up Unit, Fondazione Pisana per la Scienza, University of Pisa, Pisa, Italy

Funder

European Cooperation in Science and Technology

Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía and European Regional

Doctors Galera-Requena in cancer stem cell research

KWF Dutch Cancer Society

Associazione Italiana per la Ricerca sul Cancro AIRC

Bennink Foundation

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2024.2319340

Reference221 articles.

1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

2. Surveillance Epidemiology and End Results (SEER) Program populations (1969-2020) National Cancer Institute DCCPS Surveillance Research program. Cancer of the liver and intrahepatic bile duct - Cancer stat facts [internet]. SEER. 2022 [cited 2023 Oct 30]. Available from: https://seer.cancer.gov/statfacts/html/livibd.html

3. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

4. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

5. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to enhance the response of liver cancer to pharmacological treatments;American Journal of Physiology-Cell Physiology;2024-07-01

2. Targeting ABC transporters in PDAC - past, present, or future?;Oncotarget;2024-01-06